EUCTR2017-004651-23-FR进行中（未招募）1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer - SYNERGY trial
Institut Jules Bordet0 个研究点目标入组 180 人开始时间: 2019年6月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet all the following criteria to be eligible for the study:
- •1.Age of = 18 years
- •3.Life expectancy of a least 12 weeks
- •4.Body weight above 35kg
- •5.The locally recurrent or metastatic relapse must be histologically confirmed TNBC in patients not previously treated with systemic treatment and which cannot be treated with curative intent. Newly diagnosed patients with de-novo metastatic disease are eligible
- •6.Estrogen receptor (ER) and progesterone receptor (PR) negativity (< 1% positive staining cells in the invasive tumour) determined locally using IHC per ASCO/CAP criteria58
- •7.Human epidermal growth factor receptor 2 (HER2) negativity (negative IHC staining [score 0 or 1] or negative fluorescence in situ hybridization [FISH] based on the ASCO/CAP guidelines and recommendations from 2013) and determined locally59
- •Note: patients initially diagnosed with hormone receptor–positive and/or HER2-positive breast cancer are eligible if the tumor biopsy obtained from a local recurrence or distant metastasis site confirms the TNBC disease.
- •8.Confirmed tumour PD-L1 and CD73 IHC assessment as documented through central testing of a representative tumour tissue specimen for stratification purposes (only for phase II)
- •9.Provision of recurrence/metastatic tissue samples (at least 1 FFPE [Formalin-Fixed paraffin-embedded] tumour tissue and 1 frozen core as a priority, if feasible 2 additional fresh tumour tissue cores should be collected too) including those from resections, core-needle biopsies or excisional, incisional, punch, or forceps biopsies. Fine-needle aspiration (FNA) (defined as samples that do not preserve tissue architecture and yield cell suspension and/or smears), brushing, and cell pellets from cytology samples are not acceptable. If the patient has just performed a metastatic lesion biopsy, the patient is eligible only if an archived FFPE tissue sample (or at least 20 unstained slides, freshly cut for the purposes of the study) of the metastatic lesion is available. In this situation only, frozen/fresh cores are not mandatory. In case of a de-novo metastatic disease, a biopsy of the primary lesion (without a biopsy of a metastatic lesion) is acceptable (at least 1 FFPE tumour tissue and 1 frozen core as a priority, if feasible 2 additional fresh tumour tissue cores should be collected too).
- •10.Provision of an archived FFPE diagnostic biopsy or surgical primary tumour sample (or at least 20 unstained slides, freshly cut for the purposes of the study). In case of neoadjuvant treatment (before surgery), the diagnostic biopsy is requested (not the surgical primary tumour sample).
- •11.At least 6 months elapsed between the completion of treatment with curative intent (e.g., date of primary breast tumour surgery or date of last adjuvant or adjuvant chemotherapy administration, whichever occurred last) and first documented local or distant disease recurrence (NOTE: for de-novo metastatic disease not applicable)
- •12.At least one measurable disease based on RECIST v1.1. Tumour lesions in a previously irradiated area are considered measurable, if progression has been demonstrated in such lesions
- •13.Adequate organ function:
- •a)Absolute neutrophil count (ANC) = 1500/µl (without the addition of growth factors)
- •b)Platelets [PLT] = 100000/µl (without the addition of growth factors/prior transfusions)
- •c)Hemoglobin (Hb) = 10 g/dl (without the addition of growth factors/prior transfusions)
- •d)Creatinine = 1.5 x u
排除标准
- •Patients who exhibit any of the following conditions at screening are ineligible for admission into the study:
- •1.Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
- •a)Patients with vitiligo or alopecia
- •b)Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
- •c)Any chronic skin condition that does not require systemic therapy
- •d)Patients without active disease in the last 5 years may be included but only after consultation with the study physician
- •e)Patients with celiac disease controlled by diet alone
- •2.Current or prior treatment with immunosuppressive medication within 14 days prior to enrolment. The following are exceptions to this criterion:
- •a)Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
- •b)Systemic corticosteroids at physiologic doses not to exceed < 10 mg/day of prednisone or its equivalent
- •c)Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication
- •3.Any live, attenuated vaccine administered within 28 days prior to enrolment or anticipation that such a live attenuated vaccine will be required during the study
- •4.Chronic daily treatment with non-steroidal anti-inflammatory drug (NSAID) (occasional use for the symptomatic relief of medical conditions, for example, headache, fever is allowed)
- •5.Active infection including
- •a)Tuberculosis (TB) (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice)
- •b)Hepatitis B (known positive HBV surface antigen (HBsAg) result). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible.
- •c)Hepatitis C. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- •d)Human immunodeficiency virus (positive HIV 1/2 antibodies).
- •6.Treatment with systemic immunostimulatory agents, including but not limited to, interferon (IFN)-alpha, IFN-beta, interleukin (IL)-2, conjugated IL-2 cytokines within 42 days or five half-lives of the drug, whichever is longer, prior to screening
- •7.Previous treatment with immune checkpoint inhibitors (e.g. anti-PD-1, anti-PD-L1 including durvalumab, anti-Cytotoxic T-lymphocyte-associated molecule-4), anti-CD73 antibodies, adenosine A2A receptor antagonists, or prior treatment with CD137 agonists/OX-40 agonists or any other antibody or drug targeting T-cell co-stimulation or other immunomodulatory therapies
- •8.Any unresolved toxicity NCI CTCAE Grade = 2 from previous anticancer therapy with the exception of alopecia, vitiligo and the laboratory values defined in the inclusion criteria
- •9.Untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
- •Subjects with previously treated brain metastases with local treatment (stereotactic radiosurgery or whole brain radiation therapy) may participate provided they have stable brain metastases on a recent brain MRI (performed during the 2 weeks prior inclusion) and have measurable d
研究者
相似试验
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209
招募中
2 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer2024-511850-34-00Institut Jules Bordet209
招募中
2 期
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
进行中（未招募）
不适用
Study of Carboplatin-Paclitaxel, with or without ISIS 183750 (an eIF4E Inhibitor), in Patients with Stage IV Non-Small Cell Lung Cancer, Phase 1b/2EUCTR2010-022240-21-HUIsis Pharmaceuticals Inc.118